|
Oncology Biomarkers
MedQIA has developed a unique set of cutting-edge quantitative oncology biomarkers. These biomarkers are machine-learned from proprietary multi-modality databases that correlate early imaging features with treatment outcomes. They include prognostic, predictive and surrogate outcome biomarkers.
Predictive imaging biomarkers non-invasively predict a patient's response to a specific therapy, thus they are useful for patient eligibility and treatment planning. Surrogate outcome biomarkers provide quantitative early detection of treatment effects or disease progression. These quantitative biomarkers are calculated by computer-aided analysis systems to maximize accuracy and reproducibility, and have tremendous potential to reduce the number of subjects and shorten clinical trials.
MedQIA's Quantitative Image Analysis systems include state-of-the-art diffusion and perfusion biomarkers. The latest science is implemented in validated software according to MedQIA System Development Life Cycle (SDLC), and all computer systems are FDA 21 CFR Part 11 compliant.
MedQIA's analyses span a full range of imaging modalities and organ systems. We provide Sub-Specialty Image Interpretation through a partnership with UCLA faculty Radiologists and Oncologists.
|
